

Risk factors and clinical significances for retropancreatic lymph node metastasis in gastric cancer patients

Factores de riesgo y significado clínico de las metástasis en los ganglios linfáticos retropancreáticos en pacientes con cáncer gástrico

Aydin Yavuz*, Huseyin Gobut, Kursat Dikmen, Hasan Bostanci, Ahmet Cagri Buyukkasap, and Osman Yuksel

Department of General Surgery, Gazi University, Medical Faculty, Ankara, Turkey

Abstract

Background: The incidence of retropancreatic lymph node metastasis in gastric cancer patients is not negligible. **Objective:** The aim of present study was to determine the risk factors for retropancreatic lymph node (LN) metastasis and to investigate its clinical significance. **Method:** Clinical pathologic data of 237 patients with gastric cancer between June 2012 and June 2017 were analyzed retrospectively. **Results:** 14 patients (5.9%) had retropancreatic LN metastases. The median survival of patients with and without retropancreatic LN metastasis was 13.1 and 25.7 months. According to univariate analysis; tumor size ≥ 8 cm, Bormann type III/IV, undifferentiated type, presence of angiolymphatic invasion, depth of invasion (pT4), N3 stage, No. 3, No. 7, No. 8, No. 9, and No. 12p LN metastasis was found to be associated with retropancreatic LN metastasis. According to multivariate analysis; tumor size ≥ 8 cm, Bormann type III/IV, undifferentiated type, pT4, N3 stage, No. 9 LN metastasis, and No. 12p LN metastasis were found to be independent prognostic variables for retropancreatic LN metastasis. **Conclusions:** Retropancreatic LN metastasis is a poor prognostic factor for gastric cancer. Tumor size (≥ 8 cm), Bormann type III/IV, undifferentiated tumor, pT4, N3 stage, and No. 9 and No. 12p LN metastasis are risk factors for metastasis to retropancreatic lymph node.

Keywords: Retropancreatic lymph node. Risk factors. Incidence. Survival.

Resumen

Antecedentes: La incidencia de metástasis en ganglios linfáticos retropancreáticos en pacientes con cáncer gástrico no es despreciable. **Objetivo:** Determinar los factores de riesgo de metástasis en los ganglios linfáticos (GL) retropancreáticos e investigar su importancia clínica. **Método:** Se analizaron retrospectivamente los datos clínicos patológicos de 237 pacientes con cáncer gástrico entre junio de 2012 y junio de 2017. **Resultados:** Hubo 14 pacientes (5.9%) que presentaron metástasis de GL retropancreático. La mediana de supervivencia de los pacientes con y sin metástasis del GL retropancreático fue de 13.1 y 25.7 meses, respectivamente. Según el análisis univariado, se encontró que el tamaño tumoral ≥ 8 cm, Bormann tipo III/IV, tipo indiferenciado, presencia de invasión angiolinfática, profundidad de invasión (pT4), estadio N3 y metástasis GL No. 3, 7, 8, 9 y 12p se asociaba con metástasis de GL retropancreático. Según el análisis multivariante, se encontró que el tamaño tumoral ≥ 8 cm, Bormann tipo III/IV, tipo indiferenciado, pT4, estadio N3, metástasis de GL No. 9 y metástasis de GL No. 12p eran variables pronósticas independientes para la metástasis de GL retropancreático. **Conclusiones:** La metástasis del GL retropancreático es un factor de mal pronóstico para el cáncer gástrico. El tamaño del tumor ≥ 8 cm, el tipo III/IV de Bormann, el tumor indiferenciado, el estadio pT4, N3 y las metástasis de GL No. 9 y 12p son factores de riesgo de metástasis en los GL retropancreáticos.

Palabras clave: Ganglio linfático retropancreático. Factores de riesgo. Incidencia. Supervivencia.

*Correspondence:

Aydin Yavuz

E-mail: aydinyavuz@yahoo.com

Date of reception: 16-05-2022

Date of acceptance: 03-11-2022

DOI: 10.24875/CIRUE.M22000732

Cir Cir (Eng). 2023;91(3):630-639

Contents available at PubMed

www.cirugiaycirujanos.com

2444-0507/© 2022 Academia Mexicana de Cirugía. Published by Permanyer. This is an open access article under the terms of the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

Gastric cancers are one of the most common gastrointestinal system tumors in the world¹. In spite of advancements in the treatment modalities such as chemotherapy and radiotherapy, surgery for gastric cancers is still the most important and primary treatment. Lymph node metastasis is undoubtedly the most important independent risk factors for survival in gastric cancer²⁻⁵. The performants of D2 or D3 lymph node dissection (LND) in addition to radical gastrectomy is still controversial. Far Eastern surgeons perform gastrectomy plus D2 LND as the standard practice, whereas Western surgeons believe that D1 LND is sufficient since D2 LND and D1 LND are not superior to each other not only in terms of higher morbidity and mortality rates of D2 LND but also in terms of survival rates of patients undergone D2 LND and D1 LND⁶⁻¹⁰. However, in recent years, western centers have reported that D2 LND can be performed with low mortality and morbidity in selected patients¹¹⁻¹³. Randomized control studies have shown that D2 LND are linked to increased survival¹⁴⁻¹⁶. However, the study by Japan Clinical Oncology Group (JCOG) reported no significant difference in survival rate between patients that underwent D2 or D2 plus para-aortic LND^{17,18}. Many of these studies added para-aortic lymph node group to D2 LND. Therefore, only a few studies explaining the clinical role of lymph nodes other than para-aortic lymph nodes, especially No. 13 lymph node dissection. Wu et al. reported a significantly increase in survival in patients undergoing D3 LND¹⁵. According to the Japanese classification, D2 plus No. 13 lymph node dissection is recommended when the tumor has invaded the duodenum. Dissection of posterior pancreatic head lymph nodes in combination D2 LND and D2 plus No. 13 lymph node dissection has been reported to be beneficial for survival in advanced stage tumors with antrum localization¹⁹. The incidence of No. 13 lymph node metastasis is around 6.7%²⁰.

Considering that the incidence rate of retropancreatic lymph node metastasis is not negligible, it is important to determine the clinical significance and risk factors of this condition in terms of metastasis. The aim of this study was to determine the risk factors for retropancreatic lymph node metastasis and to investigate its clinical significance.

Materials and methods

After obtaining the approval from the Clinical Research Ethics Committee of the Gazi University (2018/107), the

treatments of a total of 315 patients with the diagnosis of gastric cancer were planned at the Gazi University Faculty of Medicine Hospital between June 2012 and June 2017. Patients with histopathologically diagnosed with gastric adenocarcinoma, tumors located in the cardia, corpus or antrum, history of no gastrectomy or other malignancy, at least D2 lymph node dissection and R0 resection were included in the study. The exclusion criteria were determined as follows according to the clinical records including the retrospectively scanned pathology reports:

- Those who have received neoadjuvant chemotherapy
- Those who death within the first postoperative 30 days
- Those who were found not to have 13th lymph node dissected
- Those who have distant organ metastasis
- Those who have positive peritoneal lavage cytology.

Finally a total of 237 patients met inclusion were enrolled and 78 patients were excluded from the study. Radical subtotal or total gastrectomy along with D2 and/or D2 plus lymph node dissection according to the Japanese Classification of Gastric Cancer Association was performed in all patients²¹. The lymph node stations in our study were defined as followed: No. 3 (lesser curvature LNs), No. 7 (LNs along the trunk of left gastric artery between its root and the origin of its ascendary branch), No. 8 (LNs along the common hepatic artery), No. 9 (celiac artery LNs), No. 12p (hepatoduodenal LNs along the portal vein), and No. 13 (LNs on the posterior of the pancreatic head cranial to duodenal papilla).

Study design

No. 13 lymph nodes are defined as lymph nodes located in the retropancreatic area. Whether or not No. 13 LN dissection was performed was retrospectively determined from the patients' pathology reports. Patients with No. 13 LN metastases were included in the No. 13 LN (+) group. Patients with No. 13 LN dissection determined in the pathology report No. 13 LN (-) were included in the patient group. No. 13 LN dissection was performed in cases where the tumor was thought to have invaded the duodenum. There were no predefined indications for the dissection of the retropancreatic lymph node. The removal of retropancreatic lymph nodes was based on the surgeons' opinion due to the tumor invasion to duodenum. No. 3, 7, 8, 9, 12p, and 13 lymph nodes dissected were determined according to the pathology

reports. The total number of dissected lymph nodes and metastatic lymph nodes were determined based on the above-mentioned stations. The patients were classified according to the presence of metastasis in No. 13 lymph nodes (13+ and 13-). Age (≤ 60 and > 60 year), gender, tumor localization (cardia, corpus, and antrum), tumor diameter (≤ 4 , 4-8, and ≥ 8 cm), differentiation type (differentiated and undifferentiated), presence of lymphovascular invasion, Bormann classification (type I/II, III/IV), Lauren's classification (intestinal, diffuse, mixed type), tumor invasion depth (T stage), nodal stage (N stage), total number of dissected and metastatic lymph nodes, post-operative pathological stage (according to the 7th edition of the AJCC gastric cancer guidelines), and total survival time of the patients were retrospectively analyzed.

The patients were followed up every 3 months in the first 1-year, every 6 months in the next 2 years, and then every following year. Tumor markers, endoscopic evaluation, abdominal, and thoracic computed tomography were measured during patients' check-ups.

The families of these cases were contacted through phone and were asked to participate after being verbally informed of the aim and methods of the study. The study was conducted in accordance with the Declaration of Helsinki. Informed contents form was obtained from all patients.

Statistical analysis

The Chi-square test was used to compare differences in the categorical data. Mann-Whitney U test was used to compare differences in the non-categorical data. Survival was compared using the log-rank test, and survival curves were generated using the Kaplan-Meier method. The life-table was used to calculate survival time. Multivariate analyses were conducted using the Cox proportional hazards regression model and forward logistic regression. Logistic regression analysis was used to determine factors associated with No. 13 LN metastasis. ($p < 0.05$) was considered statistically significant. All data were analyzed using the Statistical Package for the Social Sciences (SPSS 22.0, Armonk, NY, USA).

Results

Clinicopathological factors

The study enrolled 166 (70%) male and 71 (30%) females with an average age of 59.6 ± 12.4 years.

Table 1. The demographical and clinicopathological features

	n (%)
Age (year), median	61.0 (23-87)
Gender	
Female	71 (30)
Male	166 (70)
Tumor location	
Cardia	59 (24.9)
Corpus	86 (36.3)
Antrum	92 (38.8)
Tumor size (cm), mean $\pm$ SD	5.0 $\pm$ 2.8
Bormann Classification	
I/II	83 (35)
III/IV	140 (56.1)
Unknown	14 (5.9)
Lauren Classification	
Intestinal type	138 (58.2)
Diffuse type	82 (34.6)
Mixed type	2 (0.8)
Unknown	15 (6.3)
Histological type	
Differentiated	143 (60.3)
Undifferentiated	94 (39.7)
pT stage	
pT1	42 (17.7)
pT2	24 (10.1)
pT3	79 (33.3)
pT4	92 (38.8)
N stage	
N0	82 (34.6)
N1	36 (15.2)
N2	43 (18.1)
N3	76 (32.1)
Stage	
I	51 (21.5)
II	64 (27)
III	122 (51.5)
Harvested LN, median (range)	43 (15-94)

Fourteen patients (5.9%) were diagnosed with No. 13 LN metastasis. The tumor localization was as followed: cardia ($n = 59$, 24.9%), corpus ($n = 86$, 36.3%), or antrum ($n = 92$, 38.3%). Table 1 shows the clinicopathological characteristics of the sample. According to without No. 13 lymph node metastasis; the Bormann type ($p = 0.014$), tumor size ($p < 0.001$), Lauren classification ($p = 0.006$), histological tumor type ($p = 0.003$), presence of angiolymphatic invasion ($p < 0.001$), depth of tumor invasion ($p = 0.035$), n stage ($p < 0.001$), and exitus ($p = 0.011$) were

significantly different between the two groups. No statistically significant difference was found in terms of age, gender, tumor location, or number of removed lymph nodes between the groups (Table 2).

Factors affecting No. 13 LN metastasis

Univariate and multivariate logistic regression analysis was carried out to test the prognostic factors. The results of logistic regression analyses are presented in table 3. Univariate logistic regression analysis showed that tumor diameter, Bormann type, Lauren's type, histological type, angiolymphatic invasion, tumor invasion depth, and nodal stage were associated with No. 13 LN metastasis respectively ($p = 0.001$, $p = 0.014$, $p = 0.001$, $p = 0.002$, $p = 0.001$, $p = 0.015$, $p = 0.0001$) (Table 3). In addition, the status of all LN stations (No. 3, 7, 8, 9, and 12p) involved in the D2 dissection site affected the No. 13 lymph node in terms of metastatic ($p < 0.05$). The results of multivariate logistic regression analysis showed that tumor size of ≥ 8 cm, Bormann type III/IV, undifferentiated histological type, T3-T4 stage, N3 stage, and No. 9 and No. 12p LN metastases were independent factors for No. 13 lymph node metastasis (Table 3).

Survival significance of No. 13 LN metastasis

The survival rate between patient with and without No. 13 LN metastasis was significantly different (Fig. 1A). No 5-year survival rate was found in the patients with No. 13 LN metastasis, while 9% survival rate was found in the patients without No. 13 LN metastasis. Furthermore, patients with or without No. 13 LN metastasis were compared in terms of survival time, the survival results were poor in patients with No. 13 LN metastasis (Table 4 and Fig. 1A). Likewise, the survival time of the patients with No. 12p LN metastasis was found to be significantly poor (Table 4 and Fig. 1B). No. 13 and No. 12p LN metastasis was found to be an independent prognostic factor for survival, affecting overall survival ($p = 0.034$ and $p = 0.009$) (Table 4).

Lymph node metastasis

Table 5 shows the metastasis rates for each lymph node. The difference found between the patients with and without No. 13 LN metastasis in terms of metastasis presence in No. 7 ($p = 0.0001$), No. 8 ($p = 0.0001$), No. 9 ($p = 0.0001$), and No. 12p ($p = 0.0012$) lymph

Table 2. Comparison of clinicopathological parameters between patients with (13+) or without (13-) No. 13 LN metastasis

Parameters	13 (+)	13 (-)	p value
Age (year)			0.784*
≤ 60	6 (42.9)	111 (49.8)	
>60	8 (57.1)	112 (50.2)	
Age (year), median (range)	61.5 (42-80)	61 (23-87)	0.838†
Gender, n (%)			1.000*
Male	10 (71.4)	156 (70.0)	
Female	4 (28.6)	67 (30.0)	
Tumor location			0.281*
Cardia	1 (7.2)	58 (26)	
Corpus	6 (42.8)	80 (35.9)	
Antrum	7 (50)	85 (38.1)	
Tumor size (cm)			< 0.001*
≤ 4	3 (21.4)	106 (47.5)	
4-8	3 (21.4)	89 (39.9)	
≥ 8	8 (57.1)	28 (12.6)	
Tumor size, cm	8.25 (3.5-12)	4.5 (0.2-18)	0.001†
Bormann classification			0.014*
Type I/II	1 (7.1)	82 (36.8)	
Type III/IV	11 (78.6)	129 (57.8)	
Unknown	2 (14.3)	12 (5.4)	
Lauren classification			0.006*
Intestinal type	2 (14.3)	136 (61)	
Diffuse type	10 (71.4)	72 (32.3)	
Mixed type	-	2 (0.9)	
Unknown	2 (14.3)	13 (5.8)	
Histological type			0.003*
Differentiated	3 (21.4)	140 (62.8)	
Undifferentiated	11 (78.6)	83 (37.2)	
Angiolymphatic invasion			< 0.001*
Yes	14 (100)	119 (53.4)	
No	-	104 (46.6)	
Harvested LN			0.373*
15-25	-	25 (11.2)	
25	14 (100)	198 (88.8)	
Harvested LN, median	41.5 (28-85)	43 (15-94)	0.438†
T stage			0.035*
pT1	-	42 (18.8)	
pT2	2 (14.3)	22 (9.9)	
pT3	2 (14.3)	77 (34.5)	
pT4	10 (71.4)	82 (36.8)	
N stage			< 0.001*
N0	-	82 (36.8)	
N1	-	36 (16.1)	
N2	1 (7.1)	42 (18.8)	
N3	13 (92.9)	63 (28.3)	
TNM stage			0.001*
I	-	51 (22.9)	
II	-	64 (28.7)	
III	14 (100)	108 (48.4)	
Exitus			0.011*
Yes	10 (71.4)	80 (35.9)	
No	4 (28.6)	143 (64.1)	

*Chi-squared test.

†Mann-Whitney U test.

Table 3. Univariate and multivariate analysis of variables for No. 13 LN metastasis

Variables	Univariate Analysis			Multivariate Analysis	
	n	r value	p value	OR (95% CI)	p value
Age (year), n (%)					
≤ 60	117	0.033	0.617		
> 60	120				
Gender, n (%)					
Male	166	0.008	0.908		
Female	71				
Tumor location					
Cardia	59	0.089	0.171		
Corpus	86				
Antrum	92				
Tumor size (cm)					
≤ 4	109	0.206	0.001	1.00	
4-8	92			0.307 (0.065-1.447)	0.136
≥ 8	36			1.079 (1.012-5.283)	0.009
Bormann classification					
Type I/II	83	0.159	0.014	1.00	0.007
Type III/IV	140			1.312 (1.004-2.577)	
Unknown	14				
Lauren classification		0.218	0.001		
Intestinal type	138				
Diffuse type	82				
Mixed type	2				
Unknown	15				
Histological type					
Differentiated	143	0.199	0.002	1.00	0.001
Undifferentiated	94			1.576 (1.020-2.871)	
Angiolymphatic invasion					
+	133	0.222	0.001		
-	104				
T stage					
pT1	42	0.157	0.015	1.00	0.786
pT2	24			1.002 (0.074-1.210)	0.022
pT3	79			2.541 (1.043-4.438)	0.0001
pT4	92			4.767 (1.940-5.787)	
N stage					
N0	82	0.292	0.0001	1.00	
N1	36			1.080 (1.002-1.743)	0.743
N2	43			2.546 (1.121-9.987)	0.659
N3	76			4.054 (2.879-5.981)	0.0001
TNM stage		0.231	0.0001		
I	51			1.00	
II	64			0.986 (0.046-1.457)	0.089
III	122			5.271 (3.469-9.419)	0.0001
No. 3 LN metastasis		0.189	0.003		
+	133				
-	106				
No. 7 LN metastasis		0.416	0.0001		
+	33				
-	204				
No. 8 LN metastasis		0.416	0.0001		
+	33				
-	204				
No. 9 LN metastasis					
+	31	0.487	0.0001	1.118 (1.021-3.665)	0.015
-	206			1.00	
No. 12p LN metastasis					
+	23	0.704	0.0001	1.008 (1.010-2.174)	0.0001
-	214			1.00	




Figure 1. A: survival in 237 gastric cancer patients with and without No. 13 lymph node (LN) metastasis. There were significant differences in the 5-year survival rate between patients with and without No. 13 LN metastases (0% vs. 9%, $p = 0.010$). B: survival in 237 gastric cancer patients with and without No. 12p LN metastases. There were significant differences in the 5-year survival rate between patients with and without No. 12p LN metastases (0% vs. 8.4%, $p = 0.001$).

nodes was found to be statistically significant. Furthermore, the logistic regression analysis showed that the metastasis to No. 9 lymph node ($p = 0.015$) and No. 12p lymph node ($p = 0.001$) increased the risk of metastasis to No. 13 lymph nodes by 8.4 and 12.3 times, respectively, (Table 6).

Discussion

The extent of lymphadenectomy in gastric cancer surgery remains controversial. Compared to D1 dissection, D2 dissection is performed by Western surgeons leading to increase survival with acceptable mortality and morbidity rates. Today, D2 and D2 plus LN dissections can be performed with acceptable morbidity and mortality rates in experienced centers^{17,22}. However, only few studies have investigating the risk factors and clinical significance for retropancreatic LN metastasis after D2 plus lymph node dissection in gastric cancers. This study investigated the risk factors for No. 13 LN metastasis and the clinical significance in a patient population undergoing retropancreatic LN dissection. Retropancreatic LN metastasis is a poor prognostic factor in patients with gastric cancer. We found that there might be metastasis to the retropancreatic lymph node in the case of a tumor diameter of ≥ 8 cm, Bormann type III/IV, undifferentiated tumor, pT4, N3 stage, and No. 9 and No. 12p LN metastasis.

Kumagai et al.²³ emphasized that survival rates could increase in patients with stage 3 gastric cancer when No. 13 lymph node is dissected. Although our study did not found a significantly correlation ($p = 0.277$) between tumor localization and No. 13 LN metastasis in patients with No. 13 LN metastasis, retropancreatic LN metastasis was found in tumors located in the corpus with a rate of 42.9% in addition to tumors located in 1/3 distal. In the patients without No. 13 LN metastasis, the rate of distal tumor localization was 38.1%, whereas rate of corpus localization for tumor was 35.9%. Based on the literature, this result supports the necessity of dissecting No. 13 lymph node in corpus tumors.

The previous studies have demonstrated a correlation between tumor size and lymph node metastases around the hepatoduodenal and mesenteric arteries and veins^{23,24}. In this present study, the rate of No. 13 lymph node positivity was 57.1% in tumors with a size ≥ 8 cm, independently of localization. A tumor diameter > 8 cm is an independent prognostic factor for retropancreatic lymph node metastasis ($p = 0.009$). These results are similar to other studies^{25,26}. Based on our study, we believe that retropancreatic LN dissection is needed in tumor sizes greater 8 cm.

The rates of LN positivity around the hepatoduodenal and mesenteric artery/vein have been reported to be higher in type III/IV tumors according to the Bormann classification and in diffuse type tumors according to the Lauren's classification^{24,27}. In addition, Xue

Table 4. Univariate and multivariate Cox regression survival analysis of the 237 patients with gastric cancer

Variables	Univariate analysis			Multivariate analysis	
	n	Median OS (95% CI)	p value	Hazard ratio (95% CI)	p value
Age (year), n (%)			0.058		
≤ 60	117	24 (18.1-29.8)			
> 60	120	13 (10.1-15.8)			
Gender, n (%)			0.683		
Male	166	18 (13.7-22.2)			
Female	71	20 (15.4-24.5)			
Tumor location			0.277		
Cardia	59	15 (8.5-21.4)			
Corpus	86	20 (12.7-27.2)			
Antrum	92	19 (14.7-21.2)			
Tumor size (cm)			0.023		
≤ 4	109	20 (15.2-24.7)		-	0.215
4-8	92	20 (14.8-25.1)		0.8 (0.6-1.1)	0.177
≥ 8	36	12 (6.1-17.8)		1.3 (0.9-2.0)	
Bormann classification			0.219		
Type I/II	83	22 (13.8-30.1)			
Type III/IV	140	15 (10.3-19.6)			
Unknown	14	8 (1.8-14.1)			
Lauren classification			0.076		
Intestinal	138	21 (17.4-24.5)			
Diffus	82	14 (11.5-16.4)			
Mixed	215	9 (4.2-13.7)			
Unknown					
Histological type			0.234		
Differentiated	143	20 (15.1-24.8)			
Undifferentiated	94	14 (10.5-17.4)			
Angiolymphatic invasion			0.064		
+	133	14 (10.8-17.1)			
-	104	22 (12.7-31.2)			
T stage			0.003		
pT1	42	35 (26.8-43.1)		-	
pT2	24	16 (2.7-29.2)		1.7 (1.0-2.9)	0.026
pT3	79	15 (9.1-20.8)		1.6 (1.0-2.4)	0.019
pT4	92	14 (10.5-17.4)		1.9 (1.3-2.9)	0.001
N stage			0.004		
N0	82	22 (13.8-30.1)		-	0.930
N1	36	20 (0.8-39.1)		0.9 (0.6-1.4)	0.902
N2	43	20 (9.2-30.7)		0.9 (0.6-1.4)	0.012
N3	76	11 (8.4-13.5)		1.3 (1.1-2.7)	
TNM stage			0.006		
I	51	33 (25.1-40.8)		-	0.770
II	64	15 (12.0-17.9)		0.8 (0.3-2.0)	0.711
III	122	14 (10.8-17.1)		0.8 (0.2-2.4)	
No. 3 LN metastasis			0.018		
+	133	14 (9.6-18.3)		1.2 (0.9-1.6)	0.710
-	106	21 (12.5-29.4)			
No. 7 LN metastasis			0.034		
+	33	11 (3.1-18.8)		1.0 (0.5-1.9)	0.924
-	204	20 (15.9-24.0)			
No. 8 LN metastasis			0.019		
+	33	12 (5.4-18.5)		1.2 (0.6-2.4)	0.572
-	204	20 (15.9-24.0)			

(Continues)

Table 4. Univariate and multivariate Cox regression survival analysis of the 237 patients with gastric cancer (continued)

Variables	Univariate analysis			Multivariate analysis	
	n	Median OS (95% CI)	p value	Hazard ratio (95% CI)	p value
No. LN 9 metastasis			0.132		
+	31	14 (3.0-24.9)		0.8 (0.4-1.5)	0.545
-	206	18 (14.6-21.3)			
No. LN 12p metastasis			0.001		
+	23	7 (3.4-10.5)		1.8 (1.1-2.8)	0.009
-	214	20 (16.4-23.5)			
No. LN 13 metastasis			0.010		
+	14	5 (2.5-7.4)		1.7 (1.1-2.4)	0.034
-	223	20 (16.3-23.6)			

ALI: angiolymphatic invasion; OS: overall survival; CI: confidence interval; LN: lymph node.

Table 5. Regional LN metastasis in patients with No. 13 LN metastasis

Lymph node	LN metastasis (n)	No. 13 LN metastasis (n = 14)	p value
No. 3	131/237	13/14	0.0001
No. 7	33/237	10/14	0.0001
No. 8	33/237	10/14	0.0001
No. 9	31/237	11/14	0.0001
No. 12p	23/237	10/14	0.012

No. 3: lesser curvature; No. 7: along left gastric artery; No. 8: along hepatic artery group; No. 9: around celiac axis; No. 12p: along portal vein in the hepatoduodenal ligament.

Table 6. Logistic regression analysis of characteristics for No. 13 LN metastasis

Lymph node	B value	SE	Wald	p value	OR (95% CI)
No. 3+	0.260	1.665	0.024	0.876	1.296 (0.050-33.876)
No. 7+	2.969	2.010	2.181	0.140	19.469 (0.379-1001.118)
No. 8+	0.832	1.578	0.278	0.598	0.435 (0.020-9.601)
No. 9+	2.133	1.069	29.616	0.015	8.442 (1.502-47.460)
No. 12p+	4.816	1.126	18.293	0.001	12.324 (1.274-112.977)

A logistic regression analysis showed that each of the metastasis to the No. 9 and No. 12p LNs were a risk factor for No. 13 LN metastases (p = 0.015 and p = 0.001, respectively).

et al.²⁶ showed that the differentiation stage was associated with macroscopic type No. 13 LN metastasis. In our study, the rate of No. 13 LN metastasis in patients with Bormann III/IV stage was 78.6%. Likewise, the rate of No. 13 LN metastasis was found to be high in diffuse type tumors according to the Lauren classification (71.4%). The correlation between retropancreatic

LN metastasis and Bormann III/IV and diffuse type gastric cancers may be due to the higher prevalence of Bormann type III/IV and diffuse type tumors in advanced stage cancers²⁶. Moreover, considering histopathological tumor types, besides studies reporting that distant lymph node metastases might be higher, especially in undifferentiated tumors, there are also studies reporting low rates^{19,23,24,27}. In our study, the rate of No. 13 LN metastasis was considerably higher in patients with undifferentiated tumors than in patients with differentiated tumors (78.6% vs. 21.4%, p = 0.003). Thus, we believe that D2 plus retropancreatic LN dissection is required in Bormann type III/IV, diffuse type, and undifferentiated tumors.

As the tumor depth and the rate of LN metastasis increase independently of the localization, the rate of metastasis to distant lymph nodes such as hepatoduodenal, mesenteric artery/vein, and retropancreatic LN is also increasing^{19,23,24,27}. In our study, the rate of No. 13 LN positivity was high, especially in pT4 patients (71.4%). Furthermore, we also showed that the rate of No. 13 LN positivity was 7.1% in the case of N2 positivity, while the rate of No. 13 LN positivity was 92.9% in the case of pN3 positivity. Thus, pT and pN were an independent risk factor for No. 13 LN metastasis. Furthermore, the median survival time was 14 months (p = 0.003) for pT4 tumors and 11 months for pN3 tumors (p = 0.004). These results demonstrate that increased tumor invasion depth and advanced nodal stage are associated with a poor prognosis and a risk of retropancreatic LN metastasis. Thus, LN dissection should be extended in such patients.

There was a difference between the patients with and without No. 13 LN metastasis in terms of metastasis to No. 3, 7, 8, 9, and 12p lymph nodes. However, only

No. 9 and 12p lymph nodes were independent risk factors for retropancreatic lymph node metastasis ($p = 0.015$ and $p = 0.0001$). The intricate interactions among the lymph nodes around the stomach might explain these results. The probability of metastasis to No. 13 lymph node was closely linked to No. 9 and 12p lymph nodes and supported by other studies^{26,28}. This is possibly due to the communicating branches of lymphatic vessels among the regional lymph nodes. Especially in the case of 7, 8, 9 and 12p LN positivity, the rate of No. 13 LN metastasis was high. This result shows that 1/3 of the patients with No. 9 LN positivity have No. 13 LN positivity in advanced stage gastric cancers. Thus, if metastasis is detected in No. 9 lymph node intraoperatively, there is a possibility that metastasis is present in retropancreatic lymph node, suggesting that D2 plus lymph node dissection should be performed. Studies have shown 4.9% to 14.8% in No. 9 LN positivity, whereas we found 35.5% positivity^{19,27}. The high rate of No. 9 LN metastasis in this present study can be explained by the advanced stage of tumors in our study.

Our logistic regression analysis showed that tumor size (> 8 cm), depth of tumor invasion (pT4), higher number of LN metastasis (pN3), advanced stage, No. 3, 7, 8, 9, and 12p lymph node metastasis were risk factors for retropancreatic LN metastasis, whereas depth of tumor invasion (OR:4.767, CI:1.940-5.787, $p = 0.00021$), nodal stage (OR:4.054, CI:2.879-5.981, $p = 0.0001$), and presence of No. 9 and 12p lymph node metastasis were separately found to be an independent risk factors for retropancreatic lymph node metastasis. Furthermore, this study showed that the rate of retropancreatic lymph node positivity increased 8.4 times in the case of No. 9 lymph node positivity and 12.2 times in the case of No. 12p lymph node positivity which is similar to previous studies²⁷. The high rates in our study can be explained by the fact that the majority of our patients were diagnosed with corpus, distal and advanced stage tumors. Although it is not possible to eliminate this heterogeneity completely, the study can be made more homogeneous using patients at a single stage. Retrospective characteristic of our study, low number of patients, not specifying duodenum invasion of tumor and not indicating the status of preoperative and postoperative complications of the patients can be regarded as the limitations of our study.

Conclusions

We found a 5.9% of incidence of metastasis in No. 13 lymph node linked to a decline in survival

rates. In advanced stage gastric cancers, D2 plus LN dissection may be required in tumors located in the corpus in addition to tumors located in 1/3 distal. Moreover, it has been shown that No. 9 and 12p lymph node metastases are independent risk factors for retropancreatic lymph node metastasis, therefore suggesting that No. 13 lymph node should also be added to the lymph node dissection. In experienced centers, retropancreatic LN dissection can be performed without any increase in morbidity, especially in the case of T3, T4 and N positive tumors located in the corpus and distal, as revealed in this study. The lower survival rates of the patients with lymph node metastasis and the higher mortality rates can be explained by poor prognostic criteria such as Diffuse type, Bormann III-IV, large tumor diameter, more T3-T4, and N2-N3 tumors.

Funding

The authors declare that they have not received funding.

Conflicts of interest

The authors declare no conflicts of interest.

Ethical disclosures

Protection of human and animal subjects. The authors declare that the procedures followed were in accordance with the regulations of the relevant clinical research ethics committee and with those of the Code of Ethics of the World Medical Association (Declaration of Helsinki).

Confidentiality of data. The authors declare that they have followed the protocols of their work center on the publication of patient data.

Right to privacy and informed consent. Right to privacy and informed consent. The authors have obtained approval from the Ethics Committee for analysis and publication of routinely acquired clinical data and informed consent was not required for this retrospective observational study.

References

1. Danaei G, Hoorn SV, Lopez AD, Murray CJ, Ezzati M, Comparative Risk Assessment collaborating group (Cancers). Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors. *Lancet* 2005;366:1784-93.
2. Adachi Y, Shiraishi N, Suematsu T, Shiromizu A, Yamaguchi K, Kitano S. Most important lymph node information in gastric cancer: multivariate prognostic study. *Ann Surg Oncol* 2000;7:503-7.

3. Huang CM, Lin JX, Zheng CH, Li P, Xie JW, Lin BJ. Effect of negative lymph node count on survival for gastric cancer after curative distal gastrectomy. *Eur J Surg Oncol* 2011;37:481-7.
4. Marchet A, Mocellin S, Ambrosi A, Morgagni P, Garcea D, Marrelli D, et al. The ratio between metastatic and examined lymph nodes (N ratio) is an independent prognostic factor in gastric cancer regardless of the type of lymphadenectomy: results from an Italian multicentric study in 1853 patients. *Ann Surg* 2007;245:543-52.
5. Xu DZ, Geng QR, Long ZJ, Zhan YQ, Li W, Zhou ZW, et al. Positive lymph node ratio is an independent prognostic factor in gastric cancer after d2 resection regardless of the examined number of lymph nodes. *Ann Surg Oncol* 2009;16:319-26.
6. Bonenkamp JJ, Hermans J, Sasako M, van de Velde CJ, Welvaart K, Songun I, et al. Extended lymph-node dissection for gastric cancer. *N Engl J Med* 1999;340:908-14.
7. Bonenkamp JJ, Songun I, Hermans J, Sasako M, Welvaart K, Plukker JT, et al. Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. *Lancet* 1995;345:745-8.
8. Cuschieri A, Fayers P, Fielding J, Craven J, Bancewicz J, Joypaul V, et al. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative Group. *Lancet* 1996;347:995-9.
9. Cuschieri A, Weeden S, Fielding J, Bancewicz J, Craven J, Joypaul V, et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. *Br J Cancer* 1999;79:1522-30.
10. Dent DM, Madden MV, Price SK. Randomized comparison of R1 and R2 gastrectomy for gastric carcinoma. *Br J Surg* 1988;75:110-2.
11. Degiuli M, Sasako M, Calgaro M, Garino M, Rebecchi F, Mineccia M, et al. Morbidity and mortality after D1 and D2 gastrectomy for cancer: interim analysis of the Italian Gastric Cancer Study Group (IGCSG) randomised surgical trial. *Eur J Surg Oncol* 2004;30:303-8.
12. Degiuli M, Sasako M, Ponti A, Soldati T, Danese F, Calvo F. Morbidity and mortality after D2 gastrectomy for gastric cancer: results of the Italian Gastric Cancer Study Group prospective multicenter surgical study. *J Clin Oncol* 1998;16:1490-3.
13. Roviello F, Marrelli D, Morgagni P, de Manzoni G, Di Leo A, Vindigni C, et al. Survival benefit of extended D2 lymphadenectomy in gastric cancer with involvement of second level lymph nodes: a longitudinal multicenter study. *Ann Surg Oncol* 2002;9:894-900.
14. Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. *Lancet Oncol* 2010;11:439-49.
15. Wu CW, Hsiung CA, Lo SS, Hsieh MC, Chen JH, Li AF, et al. Nodal dissection for patients with gastric cancer: a randomised controlled trial. *Lancet Oncol* 2006;7:309-15.
16. Wu CW, Hsiung CA, Lo SS, Hsieh MC, Shia LT, Whang-Peng J. Randomized clinical trial of morbidity after D1 and D3 surgery for gastric cancer. *Br J Surg* 2004;91:283-7.
17. Sano T, Sasako M, Yamamoto S, Nashimoto A, Kurita A, Hiratsuka M, et al. Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy--Japan Clinical Oncology Group study 9501. *J Clin Oncol* 2004;22:2767-73.
18. Sasako M, Sano T, Yamamoto S, Kurokawa Y, Nashimoto A, Kurita A, et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. *N Engl J Med* 2008;359:453-62.
19. Tokunaga M, Ohyama S, Hiki N, Fukunaga T, Inoue H, Yamada K, et al. Therapeutic value of lymph node dissection in advanced gastric cancer with macroscopic duodenum invasion: is the posterior pancreatic head lymph node dissection beneficial? *Ann Surg Oncol* 2009;16:1241-6.
20. Eom BW, Joo J, Kim YW, Park B, Park JY, Yoon HM, et al. Is there any role of additional retropancreatic lymph node dissection on D2 gastrectomy for advanced gastric cancer? *Ann Surg Oncol* 2013;20:2669-75.
21. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma-2nd English edition. *Gastric Cancer* 1998;1:10-24.
22. Fujii M, Sasaki J, Nakajima T. State of the art in the treatment of gastric cancer: from the 71st Japanese Gastric Cancer Congress. *Gastric Cancer* 1999;2:151-7.
23. Kumagai K, Sano T, Hiki N, Nunobe S, Tsujiura M, Ida S, et al. Survival benefit of "D2-plus" gastrectomy in gastric cancer patients with duodenal invasion. *Gastric Cancer* 2018;21:296-302.
24. Wu L, Zhang C, Liang Y, Wang X, Ding X, Liang H. Risk factors for metastasis to No. 14v lymph node and prognostic value of 14v status for gastric cancer patients after surgery. *Jpn J Clin Oncol* 2018;48:335-42.
25. Eom BW, Joo J, Kim YW, Reim D, Park JY, Yoon HM, et al. Improved survival after adding dissection of the superior mesenteric vein lymph node (14v) to standard D2 gastrectomy for advanced distal gastric cancer. *Surgery* 2014;155:408-16.
26. Xue L, Chen XL, Zhang WH, Yang K, Chen XZ, Zhang B, et al. Risk factors and prognostic significance of retropancreatic lymph nodes in gastric adenocarcinoma. *Gastroenterol Res Pract* 2015;2015:367679.
27. Feng JF, Huang Y, Liu J, Liu H, Sheng HY, Wei WT, et al. Risk factors for No. 12p and No. 12b lymph node metastases in advanced gastric cancer in China. *Ups J Med Sci* 2013;118:9-15.
28. Wang ZC, Dong P, Gu J. No. 13 lymph node lymphadenectomy in patients of gastric carcinoma. *Chin J Gen Surg* 2009;24:362-4.